PUBLIC COMPANY
saveROCHE
USupdated 2mo ago
community read0 votes
pipeline
0
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(0)
no pipeline products on record
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →🐶 Hiring Signal
Where ROCHE is staffing up — a leading indicator of pipeline and commercial priorities.
News
- Genentech AI leader Richard Bonneau leaves pharma in latest exitIn the latest high-profile departure at Roche's Genentech unit, the pharma has parted ways with its global head of AI for drug discovery, Endpoints News has learned. Computational biologist Richard…endpoints · 7h ago
- Genentech pens $1.27B deal to access Alector’s preclinical blood-brain barrier assetAfter a series of clinical-stage failures, Alector is resetting around its preclinical blood-brain barrier delivery technology, securing a big pharma partnership along the way.biospace · 11h ago
- Roche enlists Alector in Parkinson's deal, paying $100M upfrontAlector is teaming up with another large drugmaker, fresh off the collapse of a separate partnership. Alector will get $100 million upfront from Roche in a deal centered on the biotech’s neuroscien…endpoints · 11h ago
- Optogenetics researchers win a Nobel Prize; Roche bets on Alector brain drugThe Nobel laureates “laid the foundation” for a new field of brain research, the award committee wrote. Elsewhere, Roche and CSL cut licensing deals and the FDA endorsed broader use of a Lilly medi…biopharma_dive · 12h ago
- Genentech pays Alector $100M for preclinical Parkinson’s prospectGenentech is paying Alector $100 million upfront for exclusive rights to a preclinical drug candidate that targets a driver of neurodegeneration in Parkinson’s disease.fiercebiotech · 16h ago
- Roivant, the 'inveterate drug hunters', enters commercial era with LisrayaCEO Matt Gline is juggling Roivant Sciences' first solo drug launch and several maturing programs as the hub-and-spoke company sets its sights on a massive turning point into commercial viability.biospace · 22h ago
- This week in charts: Kodiak’s big comeback and Hengrui’s dealmakingThe latest installment in BioPharma Dive’s data visualization series features a closer look at Kodiak’s stock performance and Hengrui's ties with U.S. and European drugmakers.biopharma_dive · 3d ago
- Foghorn cuts 40% of workforceFollow along as BioSpace tracks job cuts and restructuring initiatives.biospace · 3d ago
- Novartis bets up to $7.8B for an mRNA-encoded T cell engager from China’s AbogenNovartis is licensing an mRNA-based therapy designed to produce a CD3xCD19 T cell engager inside the body. Abogen Biosciences says the in vivo approach could reduce the likelihood of dangerous cyto…biospace · 3d ago
- ‘We’ve been taking our time’: Buzzy AI biotech Xaira reveals antibody platform, first taste of pipelineWhen Xaira Therapeutics first debuted in 2024 with a gobsmacking $1 billion in funding, a natural expectation would have been for a flurry of further activity to follow. Instead, the buzzy AI biote…fiercebiotech · 3d ago
comments(0)
5-min edit window · permanent after that